Cite
HARVARD Citation
Attrill, G. et al. (2022). Higher proportions of CD39+ tumor-resident cytotoxic T cells predict recurrence-free survival in patients with stage III melanoma treated with adjuvant immunotherapy. Journal for immunotherapy of cancer. 10 (6), p. . [Online].